Search results
Author(s):
Nazli Okumus
,
Ashley Park
,
Eugene Yuridistky
,
et al
Added:
6 months ago
Author(s):
Kazuya Hosokawa
,
Abe Kotaro
Added:
1 year ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3…
View more
Author(s):
Harriette Van Spall
,
Isabelle Mahé
Added:
2 months ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the…
View more
Line Melgaard
Research Area(s) / Expertise:
Author
Victor F Tapson
Job title: Professor of Medicine in the Division of Pulmonary and Critical Care Medicine
Author
Irene M Lang
Job title: Clinical Cardiologist and Professor of Vascular Biology
Author
Nils Kucher
Job title: Professor of Angiology / Director University Clinic of Angiology
Author
Mert Dumantepe
Job title: Associate Professor of Cardiovascular Surgery
Author
Author(s):
Isabelle C Van Gelder
Added:
9 months ago
ESC Congress 2024 — Chair, Prof Isabelle C Van Gelder (University of Groningen, NL) joins us to discuss key highlights from the ESC Atrial Fibrillation 2024 guidelines.The new guidelines centre on shared and equal care, patient empowerment, comorbidities and risk factor management, and evidence-based management and re-evaluation. The new AF-CARE pathway integrates comorbidity management,…
View more
Gary E Raskob
Research Area(s) / Expertise:
Job title: PhD
Author